Literature DB >> 15622015

The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations.

Irene H Richard1, Samuel Frank, Michael P McDermott, Hongkun Wang, Anne W Justus, Kori A LaDonna, Roger Kurlan.   

Abstract

BACKGROUND: Parkinson disease (PD) patients with motor fluctuations experience mood fluctuations, but studies have been limited in number and methodology.
OBJECTIVES: To better understand the phenomenology of mood, anxiety, and motor fluctuations in PD.
METHOD: Eighty-seven PD patients and 19 spouse controls completed questionnaires, rating scales, and diaries using visual analogue scales (VAS) to rate mood, anxiety, and motor states. Average daily variance in VAS scores was determined, and PD patients whose average daily variance was larger than that for all of the control subjects were considered to have fluctuations.
RESULTS: Twenty-nine percent of patients had fluctuations in anxiety, 24% motor, and 21% mood; 65% had no fluctuations. Seventy-five percent of patients with motor fluctuations had mood and/or anxiety fluctuations, but 5 subjects reported emotional fluctuations without motor fluctuations. The combination of mood and anxiety fluctuations was frequent, but anxiety and mood did not always appear to fluctuate together. Visual inspection of diaries revealed that not all patients exhibited a temporal relationship between emotional and motor fluctuations. Compared with nonfluctuators, those with mood or anxiety fluctuations were more likely to have higher scores on psychiatric rating scales, report histories of depression or anxiety, and use psychotropic medications.
CONCLUSIONS: PD patients are heterogeneous with regard to the presence, range, and pattern of fluctuations. In general, patients with mood fluctuations also have anxiety fluctuations.

Entities:  

Mesh:

Year:  2004        PMID: 15622015

Source DB:  PubMed          Journal:  Cogn Behav Neurol        ISSN: 1543-3633            Impact factor:   1.600


  23 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 2.  Recognition and management of neuropsychiatric complications in Parkinson's disease.

Authors:  Florian Ferreri; Catherine Agbokou; Serge Gauthier
Journal:  CMAJ       Date:  2006-12-05       Impact factor: 8.262

3.  Behavioral impairments and serotonin reductions in rats after chronic L-dopa.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

Review 4.  Anxiety in Parkinson's disease: identification and management.

Authors:  Jack J Chen; Laura Marsh
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

5.  Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.

Authors:  Karen L Eskow Jaunarajs; Kristin B Dupre; Corinne Y Ostock; Thomas Button; Terrence Deak; Christopher Bishop
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

6.  Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease.

Authors:  Eduardo L G Moreira; Daniel Rial; Aderbal S Aguiar; Cláudia P Figueiredo; Jarbas M Siqueira; Silvia DalBó; Heros Horst; Jade de Oliveira; Gianni Mancini; Tiago S dos Santos; Jardel G Villarinho; Francielle V Pinheiro; José Marino-Neto; Juliano Ferreira; Andreza F De Bem; Alexandra Latini; Moacir G Pizzolatti; Rosa M Ribeiro-do-Valle; Rui D S Prediger
Journal:  J Neural Transm (Vienna)       Date:  2010-10-08       Impact factor: 3.575

7.  Is there room for new non-dopaminergic treatments in Parkinson's disease?

Authors:  Manuela Pilleri; Konstantinos Koutsikos; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2012-12-11       Impact factor: 3.575

8.  Specific impairments in the recognition of emotional facial expressions in Parkinson's disease.

Authors:  Uraina S Clark; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychologia       Date:  2008-03-30       Impact factor: 3.139

9.  Perceived Treatment Status of Fluctuations in Parkinson Disease Impacts Suicidality.

Authors:  Jared T Hinkle; Kate Perepezko; Zoltan Mari; Laura Marsh; Gregory M Pontone
Journal:  Am J Geriatr Psychiatry       Date:  2018-01-31       Impact factor: 4.105

10.  Pharmacologic treatment of anxiety disorders in Parkinson disease.

Authors:  Gregory M Pontone; James R Williams; Karen E Anderson; Gary Chase; Susanne R Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Justin Palanci; Peter V Rabins; Howard D Weiss; Laura Marsh
Journal:  Am J Geriatr Psychiatry       Date:  2013-03-29       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.